Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 4/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352857 | 0.95 | IRAK4 (0.40) | DGAT1IRAK4MAPK1 | |
| SCHEMBL1353415 | 0.87 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL1368820 | 0.85 | DGAT1 (0.35) | DGAT1AXL | |
| SCHEMBL1352450 | 0.85 | DGAT1 (0.39) | DGAT1ALDH1A1MAPK1 | |
| SCHEMBL27889101 | 0.84 | DGAT1 (0.36) | DGAT1MAPK1 | |
| SCHEMBL1352864 | 0.81 | HDAC4 (0.45) | ALDH1A1 | |
| SCHEMBL1371116 | 0.81 | JAK2 (0.50) | DGAT1 | |
| Hydrochloric Acid SCHEMBL1352610 | 0.80 | PBK (0.39) | DGAT1MAPK1 | |
| SCHEMBL1352358 | 0.79 | DGAT1 (0.43) | DGAT1ALDH1A1 | |
| SCHEMBL1371149 | 0.79 | DGAT1 (0.38) | DGAT1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288097-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011144584-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288097-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | SMYD3 3197/4885DGAT1 4732/4885IRAK4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.